The stock price of Ardent Health Inc (NYSE: ARDT) has surged by 1.97 when compared to previous closing price of 12.71, but the company has seen a -2.85% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-05-23 that BRENTWOOD, Tenn.–(BUSINESS WIRE)–Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that its board of directors voted to change the Company’s name to Ardent Health, Inc., effective June 3, 2025. The updated name aligns the Company’s legal name with its practice of referring to the organization as “Ardent Health” in its communications, ensuring a clear and consist.
Is It Worth Investing in Ardent Health Inc (NYSE: ARDT) Right Now?
The price-to-earnings ratio for Ardent Health Inc (NYSE: ARDT) is above average at 8.21x. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARDT is 22.71M, and at present, short sellers hold a 6.95% of that float. The average trading volume of ARDT on June 19, 2025 was 366.49K shares.
ARDT’s Market Performance
The stock of Ardent Health Inc (ARDT) has seen a -2.85% decrease in the past week, with a -14.46% drop in the past month, and a -8.80% fall in the past quarter. The volatility ratio for the week is 2.13%, and the volatility levels for the past 30 days are at 2.24% for ARDT. The simple moving average for the past 20 days is -8.12% for ARDT’s stock, with a -16.84% simple moving average for the past 200 days.
Analysts’ Opinion of ARDT
Many brokerage firms have already submitted their reports for ARDT stocks, with JP Morgan repeating the rating for ARDT by listing it as a “Neutral.” The predicted price for ARDT in the upcoming period, according to JP Morgan is $20 based on the research report published on December 17, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARDT reach a price target of $19, previously predicting the price at $22. The rating they have provided for ARDT stocks is “Neutral” according to the report published on November 06th, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to ARDT, setting the target price at $24 in the report published on October 11th of the previous year.
ARDT Trading at -4.54% from the 50-Day Moving Average
After a stumble in the market that brought ARDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.45% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARDT starting from Webb Robert Thomas, who purchase 20,000 shares at the price of $16.98 back on Nov 08 ’24. After this action, Webb Robert Thomas now owns 40,275 shares of Ardent Health Inc, valued at $339,600 using the latest closing price.
Stock Fundamentals for ARDT
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.67 for the gross margin
The net margin for Ardent Health Inc stands at 0.04. The total capital return value is set at 0.03. Equity return is now at value 23.97, with 4.73 for asset returns.
Based on Ardent Health Inc (ARDT), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.76. The interest coverage ratio of the stock is 2.17.
Currently, EBITDA for the company is 555.92 million with net debt to EBITDA at 1.22. When we switch over and look at the enterprise to sales, we see a ratio of 0.42. The receivables turnover for the company is 7.76for trailing twelve months and the total asset turnover is 1.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.
Conclusion
In summary, Ardent Health Inc (ARDT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
